Clinical evaluation of roxithromyin in acne vulgaris: comparison of daily versus alternate day regimen
DOI:
https://doi.org/10.66344/jpad.v15i1.615Keywords:
Roxithromycin, acne vulgarisAbstract
Roxithromycin, one of the newer macrolides, has been shown to be effective in acne in some
clinical trials. These trials have been done with once or twice daily dosage schedules. As
another closely related macrolide, azithromycin, has been shown to be effective when used
on alternate days, we conducted this trial to see whether an alternate day regimen of
roxithromycin gives comparable results with those of daily regimen or not. One hundred and
forty patients were included in the study and were randomly divided in two groups. Patients
in Group-I used 300 mg of roxithromycin orally once daily for eight weeks. Those in Group-
II used 300 mg of roxithromycin orally on alternate days for eight weeks. Results could be
evaluated in 125 patients, with 15 patients lost to follow up. Out of 60 patients in Group-I,
32% showed good(>50%) improvement, 57% moderate (25-50%) and 10% slight (<25%)
improvement. Of the 65 evaluable patients in Group-II, 28% showed good, 55% moderate
and 14% slight improvement. Using chi-square tests the difference between the results of the
two groups was found to be insignificant (p>0.5). Side effects noted were transient and were
nausea, slight gastric upset and diarrhea in 10% patients in Group-I and 4.6% patients in
Group-II. In conclusion, alternate day dosage regimen is found to be almost equally effective
but safer and more economical than daily dosage regimen.
References
1. Thiboutot DM, Strauss JS. Diseases of the sebaceous glands. In: Fitzpatrick’s Dermatology in General Medicine. 6th edn. New York: McGraw-Hill; 2003. p. 672-
87.
2. Simpson NB, Cunliffe WJ. Disorders of the sebaceous glands. In: Rook’s Textbook of Dermatology, 7th edn. Oxford: Blackwell Publishing; 2004. p. 43.15-43.55.
3. Akamatsu H, Nishijima S, Akamatsu M et al. Clinical evaluation of roxithromycin in patients with acne. J Int Med Res 1996; 24:109-14.
4. Ferahbas A, Utas S, Aykol D et al. Clinical evaluation of roxithromycin: a double blind, placebo-controlled and cross-over trial in patients with acne vulgaris. J Dermatol 2004; 31: 6-9.
5. Kapadia N, Talib A. Acne treated successfully with azithromycin. Int J Dermatol 2004; 43: 766-67.
6. Fernandez-Obregon AC. Azithromycin for the treatment of acne. Int J Dermatol 2000; 39: 45-50.
7. Clark C. A suggested protocol for general practice treatment. J Dermatol Treat 1993; 4 (Suppl 2):S22-3.
8. Akamatsu H, Tomita T, Horio T. Effects of roxithromycin on the production of lipase and neutrophil chemotactic factor by P. acnes. Dermatology 2002; 204: 277-80.
9. Akamatsu H, Horio T. Concentration of roxithromycin in the lesions of acne vulgaris. J Int Med Res 2001; 29: 537-40.
10. Inni S, Nakajima T, Fukuzato Y et al. Potential anti-androgenic activity of roxithromycin in skin. J Dermatol Sci 2001; 27:147-51.
11. Parsad D, Pandhi R, Dogra S. A guide to selection and appropriate use of macrolides in skin infections. Am J Clin Dermatol 2003; 4: 389-97.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Jameel Ahmad Shaheen, Muhammad Khalid, Abdul Kareem, Mushtaq Ahmad, Noor-ul-Huda Ansari, Ishtiaq Ahmad
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
